|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007131,
umls-concept:C0038952,
umls-concept:C0045093,
umls-concept:C0205179,
umls-concept:C0268138,
umls-concept:C0871261,
umls-concept:C1333355,
umls-concept:C1333356,
umls-concept:C1413247,
umls-concept:C1516213,
umls-concept:C1704632,
umls-concept:C1705972,
umls-concept:C1706817,
umls-concept:C1707520,
umls-concept:C1882417,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-3-18
|
|
pubmed:abstractText |
Selecting patients according to key genetic characteristics may help to tailor chemotherapy and optimize the treatment in non-small cell lung cancer (NSCLC). Polymorphisms at the xeroderma pigmentosum group D (XPD), excision repair cross-complementing 1 (ERCC1), and cytidine deaminase (CDA) genes have been associated with alterations in enzymatic activity and may change sensitivity to the widely used cisplatin-gemcitabine regimen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AntonuzzoAndreaA,
pubmed-author:DanesiRomanoR,
pubmed-author:Del TaccaMarioM,
pubmed-author:Di MarsicoRobertaR,
pubmed-author:FalconeAlfredoA,
pubmed-author:GiovannettiElisaE,
pubmed-author:LaanAdrie CAC,
pubmed-author:MeyValentinaV,
pubmed-author:NannizziSaraS,
pubmed-author:OrlandiniCinziaC,
pubmed-author:PetersGodefridus JGJ,
pubmed-author:RicciardiSimonaS,
pubmed-author:TibaldiCarmeloC,
pubmed-author:VasileEnricoE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1797-803
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18347182-Adult,
pubmed-meshheading:18347182-Aged,
pubmed-meshheading:18347182-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18347182-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18347182-Cisplatin,
pubmed-meshheading:18347182-Cytidine Deaminase,
pubmed-meshheading:18347182-DNA-Binding Proteins,
pubmed-meshheading:18347182-Deoxycytidine,
pubmed-meshheading:18347182-Disease Progression,
pubmed-meshheading:18347182-Endonucleases,
pubmed-meshheading:18347182-Female,
pubmed-meshheading:18347182-Humans,
pubmed-meshheading:18347182-Lung Neoplasms,
pubmed-meshheading:18347182-Male,
pubmed-meshheading:18347182-Middle Aged,
pubmed-meshheading:18347182-Polymorphism, Single Nucleotide,
pubmed-meshheading:18347182-Prognosis,
pubmed-meshheading:18347182-Retrospective Studies,
pubmed-meshheading:18347182-Survival Analysis,
pubmed-meshheading:18347182-Treatment Outcome,
pubmed-meshheading:18347182-Xeroderma Pigmentosum Group D Protein
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
|
|
pubmed:affiliation |
Division of Oncology, Department of Oncology, Azienda USL-6 of Livorno, Livorno, Italy. tiby@katamail.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|
